Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on October 24, 2025. The filing relates to Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The Company is incorporated in Nevada and its common stock trades on the NYSE American under the symbol "TOVX."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital raising mechanism.
Material Changes and Events
On October 24, 2025, the Company filed a prospectus supplement to its effective Registration Statement on Form S-3 (File No. 333-279077). This filing authorizes the offer and sale of up to $4,019,597 of the Company's common stock through an "at-the-market" offering. The sales will be conducted through or directly to A.G.P./Alliance Global Partners (the "Sales Agent") pursuant to an Amended and Restated At Market Issuance Sales Agreement. The Sales Agent is not obligated to sell a specific amount of shares but will use commercially reasonable efforts. The Sales Agent is entitled to a commission of up to 3.0% of the gross sales price per share sold.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, operational outlook, or management commentary regarding future business performance. The document notes that the Sales Agent is deemed an "underwriter" and that the Company has agreed to provide indemnification and contribution to the Sales Agent regarding certain liabilities. The report explicitly states it does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current market price of TOVX common stock to assess the potential dilution impact of the $4,019,597 offering.
- Review the full Prospectus Supplement and the underlying Form S-3 Registration Statement for detailed use of proceeds.
- Confirm the Company's current cash position and burn rate to understand the necessity of this capital raise.
- Check for any subsequent filings regarding the actual volume of shares sold under this agreement.